➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Moodys
Merck
Baxter
Dow

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,992,110


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,992,110 protect, and when does it expire?

Patent 6,992,110 protects SAVELLA and is included in one NDA.

This patent has sixteen patent family members in nine countries.

Summary for Patent: 6,992,110
Title:Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Abstract:The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:10/623,378
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,992,110
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 6,992,110

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free MANAGEMENT OF FIBROMYALGIA (FM) ⤷  Try it Free
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free MANAGEMENT OF FIBROMYALGIA (FM) ⤷  Try it Free
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 RX Yes Yes ⤷  Try it Free ⤷  Try it Free MANAGEMENT OF FIBROMYALGIA (FM) ⤷  Try it Free
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free MANAGEMENT OF FIBROMYALGIA (FM) ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,992,110

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 552856 ⤷  Try it Free
Australia 2003268020 ⤷  Try it Free
Canada 2467356 ⤷  Try it Free
Canada 2493490 ⤷  Try it Free
China 1671368 ⤷  Try it Free
European Patent Office 1463528 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
Harvard Business School
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.